{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:09:15Z","timestamp":1791407355424,"version":"4.3.3"},"publisher-location":"Berlin, Heidelberg","reference-count":61,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642386633","type":"print"},{"value":"9783642386640","type":"electronic"}],"license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-3-642-38664-0_7","type":"book-chapter","created":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T06:57:23Z","timestamp":1380783443000},"page":"161-175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Calcium-Channel Blockers in Pulmonary Arterial Hypertension"],"prefix":"10.1007","author":[{"given":"Marie-Camille","family":"Chaumais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise Artaud","family":"Macari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,6]]},"reference":[{"key":"7_CR00071","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1056\/NEJM199911043411907","volume":"341","author":"DR Abernethy","year":"1999","unstructured":"Abernethy DR, Schwartz JB (1999) Calcium-antagonist drugs. N Engl J Med 341:1447\u20131457","journal-title":"N Engl J Med"},{"key":"7_CR00072","doi-asserted-by":"publisher","first-page":"35S","DOI":"10.1378\/chest.126.1_suppl.35S","volume":"126","author":"DB Badesch","year":"2004","unstructured":"Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, McLaughlin VV (2004) Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126:35S\u201362S","journal-title":"Chest"},{"key":"7_CR00073","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.jacc.2009.04.011","volume":"54","author":"DB Badesch","year":"2009","unstructured":"Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54:S55\u2013S66","journal-title":"J Am Coll Cardiol"},{"key":"7_CR000757","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1161\/01.CIR.99.9.1197","volume":"99","author":"RJ Barst","year":"1999","unstructured":"Barst RJ, Maislin G, Fishman AP (1999) Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99:1197\u20131208","journal-title":"Circulation"},{"key":"7_CR00074","doi-asserted-by":"publisher","first-page":"40S","DOI":"10.1016\/j.jacc.2004.02.032","volume":"43","author":"RJ Barst","year":"2004","unstructured":"Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43:40S\u201347S","journal-title":"J Am Coll Cardiol"},{"key":"7_CR00075","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","volume":"54","author":"RJ Barst","year":"2009","unstructured":"Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54:S78\u2013S84","journal-title":"J Am Coll Cardiol"},{"key":"7_CR000758","doi-asserted-by":"publisher","first-page":"d1697","DOI":"10.2741\/bers","volume":"7","author":"DM Bers","year":"2002","unstructured":"Bers DM (2002) Sarcoplasmic reticulum Ca release in intact ventricular myocytes. Front Biosci 7:d1697\u2013d1711","journal-title":"Front Biosci"},{"key":"7_CR00076","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pbiomolbio.2005.01.001","volume":"91","author":"F Brette","year":"2006","unstructured":"Brette F, Leroy J, Le Guennec JY, Salle L (2006) Ca2+ currents in cardiac myocytes: old story, new insights. Prog Biophys Mol Biol 91:1\u201382","journal-title":"Prog Biophys Mol Biol"},{"key":"7_CR00077","doi-asserted-by":"publisher","first-page":"a003947","DOI":"10.1101\/cshperspect.a003947","volume":"3","author":"WA Catterall","year":"2011","unstructured":"Catterall WA (2011) Voltage-gated calcium channels. Cold Spring Harb Perspect Biol 3:a003947","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"7_CR00078","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1124\/pr.57.4.5","volume":"57","author":"WA Catterall","year":"2005","unstructured":"Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J (2005) International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 57:411\u2013425","journal-title":"Pharmacol Rev"},{"key":"7_CR00079","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/0165-6147(93)90181-I","volume":"14","author":"KG Chandy","year":"1993","unstructured":"Chandy KG, Gutman GA (1993) Nomenclature for mammalian potassium channel genes. Trends Pharmacol Sci 14:434","journal-title":"Trends Pharmacol Sci"},{"key":"7_CR000710","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4899-1775-1_2","volume":"4","author":"M De Waard","year":"1996","unstructured":"De Waard M, Gurnett CA, Campbell KP (1996) Structural and functional diversity of voltage-activated calcium channels. Ion Channels 4:41\u201387","journal-title":"Ion Channels"},{"key":"7_CR000711","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0022-3565(24)37960-1","volume":"288","author":"S Doppenschmitt","year":"1999","unstructured":"Doppenschmitt S, Langguth P, Regardh CG, Andersson TB, Hilgendorf C, Spahn-Langguth H (1999) Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. J Pharmacol Exp Ther 288:348\u2013357","journal-title":"J Pharmacol Exp Ther"},{"key":"7_CR000712","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1751-7176.2011.00513.x","volume":"13","author":"WJ Elliott","year":"2011","unstructured":"Elliott WJ, Ram CV (2011) Calcium channel blockers. J Clin Hypertens (Greenwich) 13:687\u2013689","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"7_CR000713","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1161\/CIRCULATIONAHA.105.601930","volume":"113","author":"CG Elliott","year":"2006","unstructured":"Elliott CG, Glissmeyer EW, Havlena GT, Carlquist J, McKinney JT, Rich S, McGoon MD, Scholand MB, Kim M, Jensen RL, Schmidt JW, Ward K (2006) Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation 113:2509\u20132515","journal-title":"Circulation"},{"key":"7_CR000714","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0896-6273(00)81057-0","volume":"25","author":"EA Ertel","year":"2000","unstructured":"Ertel EA, Campbell KP, Harpold MM, Hofmann F, Mori Y, Perez-Reyes E, Schwartz A, Snutch TP, Tanabe T, Birnbaumer L, Tsien RW, Catterall WA (2000) Nomenclature of voltage-gated calcium channels. Neuron 25:533\u2013535","journal-title":"Neuron"},{"key":"7_CR000715","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1378\/chest.83.4.708","volume":"83","author":"HW Farber","year":"1983","unstructured":"Farber HW, Karlinsky JB, Faling LJ (1983) Fatal outcome following nifedipine for pulmonary hypertension. Chest 83:708\u2013709","journal-title":"Chest"},{"key":"7_CR000716","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1001\/jama.284.24.3160","volume":"284","author":"S Gaine","year":"2000","unstructured":"Gaine S (2000) Pulmonary hypertension. JAMA 284:3160\u20133168","journal-title":"JAMA"},{"key":"7_CR000717","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.ehj.2004.09.014","volume":"25","author":"N Galie","year":"2004","unstructured":"Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25:2243\u20132278","journal-title":"Eur Heart J"},{"key":"7_CR000718","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"N Galie","year":"2009","unstructured":"Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493\u20132537","journal-title":"Eur Heart J"},{"key":"7_CR000719","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1161\/CIRCULATIONAHA.106.674002","volume":"118","author":"HA Ghofrani","year":"2008","unstructured":"Ghofrani HA, Wilkins MW, Rich S (2008) Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 118:1195\u20131201","journal-title":"Circulation"},{"key":"7_CR000759","volume-title":"Ion flux in pulmonary vascular control","author":"BM Groves","year":"1993","unstructured":"Groves BM, Badesch DB, Turkevich D et al (1993) Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival. In: Weir K (ed) Ion flux in pulmonary vascular control. Plenum, New York"},{"key":"7_CR000720","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1600-0773.1992.tb00552.x","volume":"71","author":"S Herzig","year":"1992","unstructured":"Herzig S, Lullmann H, Sieg H (1992) Frequency- and potential-dependency of the negative inotropic action of various dihydropyridine and non-dihydropyridine calcium antagonists. Pharmacol Toxicol 71:229\u2013235","journal-title":"Pharmacol Toxicol"},{"key":"7_CR000721","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev.pharmtox.37.1.361","volume":"37","author":"GH Hockerman","year":"1997","unstructured":"Hockerman GH, Peterson BZ, Johnson BD, Catterall WA (1997) Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol 37:361\u2013396","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"7_CR000722","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0735-1097(99)00494-5","volume":"35","author":"MM Hoeper","year":"2000","unstructured":"Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, Niedermeyer J, Fabel H, Seeger W (2000) A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 35:176\u2013182","journal-title":"J Am Coll Cardiol"},{"key":"7_CR000723","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1146\/annurev.ne.17.030194.002151","volume":"17","author":"F Hofmann","year":"1994","unstructured":"Hofmann F, Biel M, Flockerzi V (1994) Molecular basis for Ca2+ channel diversity. Annu Rev Neurosci 17:399\u2013418","journal-title":"Annu Rev Neurosci"},{"key":"7_CR000724","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1050-1738(96)00109-0","volume":"6","author":"MM Hosey","year":"1996","unstructured":"Hosey MM, Chien AJ, Puri TS (1996) Structure and regulation of L-type calcium channels a current assessment of the properties and roles of channel subunits. Trends Cardiovasc Med 6:265\u2013273","journal-title":"Trends Cardiovasc Med"},{"key":"7_CR000725","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/00005792-198601000-00004","volume":"65","author":"JD Hughes","year":"1986","unstructured":"Hughes JD, Rubin LJ (1986) Primary pulmonary hypertension. An analysis of 28 cases and a review of the literature. Medicine (Baltimore) 65:56\u201372","journal-title":"Medicine (Baltimore)"},{"key":"7_CR000726","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s00125-001-0765-6","volume":"45","author":"S Jesmin","year":"2002","unstructured":"Jesmin S, Sakuma I, Hattori Y, Fujii S, Kitabatake A (2002) Long-acting calcium channel blocker benidipine suppresses expression of angiogenic growth factors and prevents cardiac remodelling in a Type II diabetic rat model. Diabetologia 45:402\u2013415","journal-title":"Diabetologia"},{"key":"7_CR000727","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1183\/09031936.00169608","volume":"33","author":"ZC Jing","year":"2009","unstructured":"Jing ZC, Jiang X, Han ZY, Xu XQ, Wang Y, Wu Y, Lv H, Ma CR, Yang YJ, Pu JL (2009) Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 33:1354\u20131360","journal-title":"Eur Respir J"},{"key":"7_CR000728","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0968-0896(00)82134-3","volume":"1","author":"SD Kimball","year":"1993","unstructured":"Kimball SD, Hunt JT, Barrish JC, Das J, Floyd DM, Lago MW, Lee VG, Spergel SH, Moreland S, Hedberg SA et al (1993) 1-Benzazepin-2-one calcium channel blockers \u2013 VI. Receptor-binding model and possible relationship to desmethoxyverapamil. Bioorg Med Chem 1:285\u2013307","journal-title":"Bioorg Med Chem"},{"key":"7_CR000729","first-page":"545","volume":"37","author":"J Kuhlmann","year":"1987","unstructured":"Kuhlmann J (1987) Effects of quinidine, verapamil and nifedipine on the pharmacokinetics and pharmacodynamics of digitoxin during steady state conditions. Arzneimittelforschung 37:545\u2013548","journal-title":"Arzneimittelforschung"},{"key":"7_CR000730","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/sj.bjp.0704398","volume":"134","author":"J Kyselovic","year":"2001","unstructured":"Kyselovic J, Krenek P, Wibo M, Godfraind T (2001) Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats. Br J Pharmacol 134:1516\u20131522","journal-title":"Br J Pharmacol"},{"key":"7_CR000731","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/302790a0","volume":"302","author":"KS Lee","year":"1983","unstructured":"Lee KS, Tsien RW (1983) Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature 302:790\u2013794","journal-title":"Nature"},{"key":"7_CR000732","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1152\/physrev.1994.74.2.365","volume":"74","author":"TF McDonald","year":"1994","unstructured":"McDonald TF, Pelzer S, Trautwein W, Pelzer DJ (1994) Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev 74:365\u2013507","journal-title":"Physiol Rev"},{"key":"7_CR000733","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S0025-6196(12)62055-2","volume":"59","author":"MD McGoon","year":"1984","unstructured":"McGoon MD, Vlietstra RE (1984) Vasodilator therapy for primary pulmonary hypertension. Mayo Clin Proc 59:672\u2013677","journal-title":"Mayo Clin Proc"},{"key":"7_CR000734","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","volume":"53","author":"VV McLaughlin","year":"2009","unstructured":"McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J (2009) ACCF\/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53:1573\u20131619","journal-title":"J Am Coll Cardiol"},{"key":"7_CR000735","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1097\/00004872-200409000-00002","volume":"22","author":"PA Meredith","year":"2004","unstructured":"Meredith PA, Elliott HL (2004) Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. J Hypertens 22:1641\u20131648","journal-title":"J Hypertens"},{"key":"7_CR000736","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1093\/eurheartj\/ehq170","volume":"31","author":"D Montani","year":"2010","unstructured":"Montani D, Savale L, Natali D, Jais X, Herve P, Garcia G, Humbert M, Simonneau G, Sitbon O (2010) Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 31:1898\u20131907","journal-title":"Eur Heart J"},{"key":"7_CR000737","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.rmed.2003.09.019","volume":"98","author":"J Morales-Blanhir","year":"2004","unstructured":"Morales-Blanhir J, Santos S, de Jover L, Sala E, Pare C, Roca J, Rodriguez-Roisin R, Barbera JA (2004) Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 98:225\u2013234","journal-title":"Respir Med"},{"key":"7_CR000738","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0272-5231(05)70288-4","volume":"22","author":"R Naeije","year":"2001","unstructured":"Naeije R, Vachiery JL (2001) Medical therapy of pulmonary hypertension. Conventional therapies. Clin Chest Med 22:517\u2013527","journal-title":"Clin Chest Med"},{"key":"7_CR000739","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1378\/chest.107.1.54","volume":"107","author":"M Nootens","year":"1995","unstructured":"Nootens M, Schrader B, Kaufmann E, Vestal R, Long W, Rich S (1995) Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 107:54\u201357","journal-title":"Chest"},{"key":"7_CR000740","doi-asserted-by":"publisher","first-page":"196B","DOI":"10.1016\/0002-9149(85)90631-9","volume":"55","author":"M Packer","year":"1985","unstructured":"Packer M (1985) Therapeutic application of calcium-channel antagonists for pulmonary hypertension. Am J Cardiol 55:196B\u2013201B","journal-title":"Am J Cardiol"},{"key":"7_CR000741","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/NEJM198206033062203","volume":"306","author":"M Packer","year":"1982","unstructured":"Packer M, Greenberg B, Massie B, Dash H (1982) Deleterious effects of hydralazine in patients with pulmonary hypertension. N Engl J Med 306:1326\u20131331","journal-title":"N Engl J Med"},{"key":"7_CR000742","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/hrt.52.1.106","volume":"52","author":"M Packer","year":"1984","unstructured":"Packer M, Medina N, Yushak M, Wiener I (1984) Detrimental effects of verapamil in patients with primary pulmonary hypertension. Br Heart J 52:106\u2013111","journal-title":"Br Heart J"},{"key":"7_CR000743","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1056\/NEJM199309093291117","volume":"329","author":"J Partanen","year":"1993","unstructured":"Partanen J, Nieminen MS, Luomanmaki K (1993) Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine. N Engl J Med 329:812, author reply 812\u2013813","journal-title":"N Engl J Med"},{"key":"7_CR000760","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1161\/01.CIR.93.3.484","volume":"93","author":"O Raffy","year":"1996","unstructured":"Raffy O, Azarian R, Brenot F, Parent F, Sitbon O, Petitpretz P, Herv\u00e9 P, Duroux P, Dinh-Xuan AT, Simonneau G (1996) Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 93:484\u2013488","journal-title":"Circulation"},{"key":"7_CR000744","first-page":"342","volume":"134","author":"JT Reeves","year":"1986","unstructured":"Reeves JT, Groves BM, Turkevich D (1986) The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis 134:342\u2013346","journal-title":"Am Rev Respir Dis"},{"key":"7_CR000745","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S0735-1097(98)00361-1","volume":"32","author":"MJ Ricciardi","year":"1998","unstructured":"Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M (1998) Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 32:1068\u20131073","journal-title":"J Am Coll Cardiol"},{"key":"7_CR000746","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1161\/01.CIR.76.1.135","volume":"76","author":"S Rich","year":"1987","unstructured":"Rich S, Brundage BH (1987) High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 76:135\u2013141","journal-title":"Circulation"},{"key":"7_CR000747","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1056\/NEJM199207093270203","volume":"327","author":"S Rich","year":"1992","unstructured":"Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76\u201381","journal-title":"N Engl J Med"},{"key":"7_CR000748","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.healun.2008.02.009","volume":"27","author":"EB Rosenzweig","year":"2008","unstructured":"Rosenzweig EB, Morse JH, Knowles JA, Chada KK, Khan AM, Roberts KE, McElroy JJ, Juskiw NK, Mallory NC, Rich S, Diamond B, Barst RJ (2008) Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 27:668\u2013674","journal-title":"J Heart Lung Transplant"},{"key":"7_CR000749","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJM199701093360207","volume":"336","author":"LJ Rubin","year":"1997","unstructured":"Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336:111\u2013117","journal-title":"N Engl J Med"},{"key":"7_CR000750","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/0002-8703(80)90246-X","volume":"100","author":"LJ Rubin","year":"1980","unstructured":"Rubin LJ, Peter RH (1980) Primary pulmonary hypertension: new approaches to therapy. Am Heart J 100:757\u2013759","journal-title":"Am Heart J"},{"key":"7_CR000751","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1164\/ajrccm.151.2.7842196","volume":"151","author":"O Sitbon","year":"1995","unstructured":"Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, Herve P, Raffestin B, Simonneau G (1995) Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 151:384\u2013389","journal-title":"Am J Respir Crit Care Med"},{"key":"7_CR000752","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1183\/09031936.98.12020265","volume":"12","author":"O Sitbon","year":"1998","unstructured":"Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 12:265\u2013270","journal-title":"Eur Respir J"},{"key":"7_CR000753","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","volume":"111","author":"O Sitbon","year":"2005","unstructured":"Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105\u20133111","journal-title":"Circulation"},{"key":"7_CR000754","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1164\/rccm.200712-1807OC","volume":"177","author":"B Sztrymf","year":"2008","unstructured":"Sztrymf B, Coulet F, Girerd B, Yaici A, Jais X, Sitbon O, Montani D, Souza R, Simonneau G, Soubrier F, Humbert M (2008) Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 177:1377\u20131383","journal-title":"Am J Respir Crit Care Med"},{"key":"7_CR000761","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1146\/annurev.ph.45.030183.002013","volume":"45","author":"RW Tsien","year":"1983","unstructured":"Tsien RW (1983) Calcium channels in excitable cell membranes. Annu Rev Physiol 45:341\u2013358","journal-title":"Annu Rev Physiol"},{"key":"7_CR000755","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/hrt.75.2.171","volume":"75","author":"PA Woodmansey","year":"1996","unstructured":"Woodmansey PA, O\u2019Toole L, Channer KS, Morice AH (1996) Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension. Heart 75:171\u2013173","journal-title":"Heart"},{"issue":"12","key":"7_CR000756","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.amjcard.2012.02.026","volume":"109","author":"XR Zuo","year":"2012","unstructured":"Zuo XR, Zhang R, Jiang X, Li XL, Zong F, Xie WP, Wang H, Jing ZC (2012) Usefulness of intravenous adenosine in idiopathic pulmonary arterial hypertension as a screening agent for identifying long-term responders to calcium channel blockers. Am J Cardiol 109(12):1801\u20131806","journal-title":"Am J Cardiol"}],"container-title":["Handbook of Experimental Pharmacology","Pharmacotherapy of Pulmonary Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-38664-0_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T07:43:22Z","timestamp":1749023002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-38664-0_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"ISBN":["9783642386633","9783642386640"],"references-count":61,"aliases":["10.1007\/978-3-662-45805-1_7"],"URL":"https:\/\/doi.org\/10.1007\/978-3-642-38664-0_7","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]},"assertion":[{"value":"6 August 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}